

# Vincenzo Mazzaferro

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4317462/publications.pdf>

Version: 2024-02-01

334  
papers

66,702  
citations

3525

90  
h-index

750

250  
g-index

336  
all docs

336  
docs citations

336  
times ranked

40459  
citing authors

#	ARTICLE	IF	CITATIONS
1	Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification. Gut, 2023, 72, 129-140.	6.1	90
2	Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications. Gut, 2023, 72, 736-748.	6.1	42
3	The role of lymphadenectomy in the surgical treatment of intrahepatic cholangiocarcinoma: A review. European Journal of Surgical Oncology, 2022, 48, 150-159.	0.5	19
4	Is minimally invasive liver surgery a reasonable option in recurrent HCC? A snapshot from the I Go MILS registry. Updates in Surgery, 2022, 74, 87-96.	0.9	10
5	Pancreaticoduodenectomy in octogenarians: The importance of "biological age" on clinical outcomes. Surgical Oncology, 2022, 40, 101688.	0.8	7
6	Long Term Survival Analysis in a Cohort of 125 Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using Small Drug Eluting Beads. CardioVascular and Interventional Radiology, 2022, 45, 54-61.	0.9	0
7	BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. Journal of Hepatology, 2022, 76, 681-693.	1.8	1,495
8	Immunotherapies for hepatocellular carcinoma. Nature Reviews Clinical Oncology, 2022, 19, 151-172.	12.5	643
9	The EASL "Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet, The, 2022, 399, 61-116.	6.3	257
10	Impact of Surgical Margins on Overall Survival after Gastrectomy for Gastric Cancer: A Validation of Japanese Gastric Cancer Association Guidelines on a Western Series. Annals of Surgical Oncology, 2022, 29, 3096-3108.	0.7	10
11	ASO Visual Abstract: Impact of Surgical Margins on Overall Survival After Gastrectomy for Gastric Cancer: A Validation of Japanese Gastric Cancer Association Guidelines on a Western Series. Annals of Surgical Oncology, 2022, 29, 3111.	0.7	1
12	Radioembolization of Hepatocellular Carcinoma with 90Y Glass Microspheres: No Advantage of Voxel Dosimetry with Respect to Mean Dose in Dose-Response Analysis with Two Radiological Methods. Cancers, 2022, 14, 959.	1.7	11
13	Migration rate using Fully-covered metal stent in anastomotic strictures after liver transplantation: Results from the <sc>BASALT</sc> Study Group. Liver International, 2022, , .	1.9	3
14	ASO Author Reflections: Less is more: Organ-Sparing Approach for the Surgical Treatment of Gastric Adenocarcinoma. Annals of Surgical Oncology, 2022, 29, 3109-3110.	0.7	1
15	Acquired Resistance Mechanisms to PD-L1 Blockade in a Patient With Microsatellite Instability-High Extrahepatic Cholangiocarcinoma. JCO Precision Oncology, 2022, 6, e2100472.	1.5	2
16	Variations in risk-adjusted outcomes following 4318 laparoscopic liver resections. Journal of Hepato-Biliary-Pancreatic Sciences, 2022, 29, 521-530.	1.4	6
17	Impact of Diabetes and Metformin Use on Enteropancreatic Neuroendocrine Tumors: Post Hoc Analysis of the CLARINET Study. Cancers, 2022, 14, 69.	1.7	9
18	<sc>MGMT</sc> inactivation as a new biomarker in patients with advanced biliary tract cancers. Molecular Oncology, 2022, 16, 2733-2746.	2.1	2

#	ARTICLE	IF	CITATIONS
19	Utility of the Iwate difficulty scoring system for laparoscopic right posterior sectionectomy: do surgical outcomes differ for tumors in segments VI and VII?. Surgical Endoscopy and Other Interventional Techniques, 2022, 36, 9204-9214.	1.3	3
20	DNA Methylation Profiling of Human Hepatocarcinogenesis. Hepatology, 2021, 74, 183-199.	3.6	42
21	Preoperative predictors of liver decompensation after mini-invasive liver resection. Surgical Endoscopy and Other Interventional Techniques, 2021, 35, 718-727.	1.3	10
22	Laparoscopic and open liver resection for hepatocellular carcinoma with Child-Pugh B cirrhosis: multicentre propensity score-matched study. British Journal of Surgery, 2021, 108, 196-204.	0.1	76
23	ASO Author Reflections: Amid Anatomic Restrictions, Three-Dimensional Surgical Planning Eases En Bloc Resection of the Retro-Hepatic Vena Cava and the Caudate Lobe of the Liver. Annals of Surgical Oncology, 2021, 28, 6850-6851.	0.7	0
24	Resection of Retro-Hepatic Vena Cava (RHVC) En-bloc with Caudate Lobe without Vascular Exclusion for a Low Grade Leiomyosarcoma of Inferior Vena Cava. Annals of Surgical Oncology, 2021, 28, 6848-6849.	0.7	3
25	Liver resection for perihilar cholangiocarcinoma: Impact of biliary drainage failure on postoperative outcome. Results of an Italian multicenter study. Surgery, 2021, 170, 383-389.	1.0	10
26	Improved management of grade B biliary leaks after complex liver resections using gadoxetic acid disodium-enhanced magnetic resonance cholangiography. Surgery, 2021, 170, 499-506.	1.0	2
27	Postrecurrence Survival After Liver Transplantation for Liver Metastases From Neuroendocrine Tumors. Transplantation, 2021, 105, 2579-2586.	0.5	13
28	The Italian Consensus on minimally invasive simultaneous resections for synchronous liver metastasis and primary colorectal cancer: A Delphi methodology. Updates in Surgery, 2021, 73, 1247-1265.	0.9	33
29	Inter-center agreement of mRECIST in transplanted patients for hepatocellular carcinoma. European Radiology, 2021, 31, 8903-8912.	2.3	3
30	Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study. Liver Transplantation, 2021, 27, 1767-1778.	1.3	19
31	Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy.. , 2021, 9, e003311.		66
32	Cancer-derived EVs show tropism for tissues at early stage of neoplastic transformation. Nanotheranostics, 2021, 5, 1-7.	2.7	13
33	Transplant Oncology in Primary and Metastatic Liver Tumors. Annals of Surgery, 2021, 273, 483-493.	2.1	33
34	Quantitative assessment of the impact of COVID-19 pandemic on pancreatic surgery: an Italian multicenter analysis of 1423 cases from 10 tertiary referral centers. Updates in Surgery, 2021, , 1.	0.9	6
35	Development of a nomogram to predict outcome after liver resection for hepatocellular carcinoma in Child-Pugh B cirrhosis. Journal of Hepatology, 2020, 72, 75-84.	1.8	105
36	Surgical Management of Hepatic Benign Disease: Have the Number of Liver Resections Increased in the Era of Minimally Invasive Approach? Analysis from the I Go MILS (Italian Group of Minimally Invasive) Tj ETQq0 0 0 r0BT /Overlock 10 Tf 5		

#	ARTICLE	IF	CITATIONS
37	Risk-adjusted benchmarks in laparoscopic liver surgery in a national cohort. British Journal of Surgery, 2020, 107, 845-853.	0.1	29
38	Multicentre evaluation of case volume in minimally invasive hepatectomy. British Journal of Surgery, 2020, 107, 443-451.	0.1	18
39	The chances of hepatic resection curing hepatocellular carcinoma. Journal of Hepatology, 2020, 72, 711-717.	1.8	41
40	Response and relapse rates after treatment with long-acting somatostatin analogs in multifocal or recurrent type 1 gastric carcinoids: A systematic review and meta-analysis. United European Gastroenterology Journal, 2020, 8, 140-147.	1.6	17
41	mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors. Annals of Surgery, 2020, 272, 855-862.	2.1	85
42	A Combined Approach to Priorities of Surgical Oncology During the COVID-19 Epidemic. Annals of Surgery, 2020, 272, e84-e86.	2.1	16
43	Liver transplantation for hepatocellular carcinoma after successful treatment of macrovascular invasion: a multi-center retrospective cohort study. Transplant International, 2020, 33, 567-575.	0.8	44
44	Copy-Number Alteration Burden Differentially Impacts Immune Profiles and Molecular Features of Hepatocellular Carcinoma. Clinical Cancer Research, 2020, 26, 6350-6361.	3.2	35
45	Minimally Invasive Stage 1 to Protect Against the Risk of Liver Failure: Results from the Hepatocellular Carcinoma Series of the Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy Italian Registry. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2020, 30, 1082-1089.	0.5	13
46	Development and Validation of a Comprehensive Model to Estimate Early Allograft Failure Among Patients Requiring Early Liver Transplant. JAMA Surgery, 2020, 155, e204095.	2.2	67
47	Mortality after Transplantation for Hepatocellular Carcinoma: A Study from the European Liver Transplant Registry. Liver Cancer, 2020, 9, 455-467.	4.2	8
48	Combined immunotherapy and VEGF-antagonist in hepatocellular carcinoma: a step forward. Lancet Oncology, The, 2020, 21, 740-741.	5.1	8
49	Radioembolization of hepatocarcinoma with 90Y glass microspheres: treatment optimization using the dose-toxicity relationship. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 3018-3032.	3.3	44
50	Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. Lancet Oncology, The, 2020, 21, 947-956.	5.1	166
51	Liver resection and transplantation for intrahepatic cholangiocarcinoma. Journal of Hepatology, 2020, 72, 364-377.	1.8	177
52	COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy. The Lancet Gastroenterology and Hepatology, 2020, 5, 532-533.	3.7	217
53	Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant. Journal of Hepatology, 2020, 73, 342-348.	1.8	49
54	HCC recurrence in HCV-infected patients after liver transplantation: SiLVER Study reveals benefits of sirolimus in combination with CNIs: a post-hoc analysis. Transplant International, 2020, 33, 917-924.	0.8	4

#	ARTICLE	IF	CITATIONS
55	Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan. <i>Clinical Colorectal Cancer</i> , 2020, 19, 156-164.	1.0	16
56	Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference. <i>Transplantation</i> , 2020, 104, 1136-1142.	0.5	105
57	Liver transplantation as last-resort treatment for patients with bile duct injuries following cholecystectomy: a multicenter analysis. <i>Annals of Gastroenterology</i> , 2020, 34, 111-118.	0.4	1
58	Liver Resection and Transplantation for Metastases from Gastroenteropancreatic Neuroendocrine Tumors. <i>Updates in Surgery Series</i> , 2020, , 221-233.	0.0	0
59	Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. <i>Gut</i> , 2019, 68, 1065-1075.	6.1	195
60	Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials. <i>British Journal of Cancer</i> , 2019, 121, 340-343.	2.9	62
61	Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma. <i>American Journal of Pathology</i> , 2019, 189, 2090-2101.	1.9	17
62	Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation. <i>American Journal of Transplantation</i> , 2019, 19, 3176-3184.	2.6	60
63	Comparison Between Swan-Ganz Catheter and Minimally Invasive Hemodynamic Monitoring During Liver Transplantation: Report of a Monocentric Case Series. <i>Transplantation Proceedings</i> , 2019, 51, 2943-2947.	0.3	3
64	Heterologous and cross-species tropism of cancer-derived extracellular vesicles. <i>Theranostics</i> , 2019, 9, 5681-5693.	4.6	48
65	Microenvironment and tumor inflammatory features improve prognostic prediction in gastroenteropancreatic neuroendocrine neoplasms. <i>Journal of Pathology: Clinical Research</i> , 2019, 5, 217-226.	1.3	29
66	Assessing Competing Risks for Death Following Liver Transplantation for Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1001-1007.	1.1	11
67	The Italian Rare Pancreatic Exocrine Cancer Initiative. <i>Tumori</i> , 2019, 105, 353-358.	0.6	7
68	A national mandatory-split liver policy: A report from the Italian experience. <i>American Journal of Transplantation</i> , 2019, 19, 2029-2043.	2.6	52
69	First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. <i>Cancer Discovery</i> , 2019, 9, 1696-1707.	7.7	157
70	Permanent Pancreatic Duct Occlusion With Neoprene-based Glue Injection After Pancreatoduodenectomy at High Risk of Pancreatic Fistula. <i>Annals of Surgery</i> , 2019, 270, 791-798.	2.1	25
71	Laparoscopic liver resection of hepatocellular carcinoma located in unfavorable segments: a propensity score-matched analysis from the I Go MILS (Italian Group of Minimally Invasive Liver) Tj ETQq1 1 0.784314rgBT /Overlock 10	1.4	10
72	Extracellular vesicles enhance the targeted delivery of immunogenic oncolytic adenovirus and paclitaxel in immunocompetent mice. <i>Journal of Controlled Release</i> , 2019, 294, 165-175.	4.8	93

#	ARTICLE	IF	CITATIONS
73	Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases. <i>Clinical Colorectal Cancer</i> , 2019, 18, 34-43.e6.	1.0	7
74	Multicenter validation of a score to predict prognosis after the development of HCC recurrence following liver transplantation. <i>Hpb</i> , 2019, 21, 731-738.	0.1	24
75	Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. <i>British Journal of Cancer</i> , 2019, 120, 165-171.	2.9	279
76	Ki-67 and presence of liver metastases identify different progression-risk classes in pancreatic neuroendocrine neoplasms (pNEN) undergoing resection. <i>European Journal of Surgical Oncology</i> , 2019, 45, 755-760.	0.5	14
77	Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs). <i>International Journal of Cancer</i> , 2019, 144, 1704-1712.	2.3	20
78	Endo-therapies for biliary duct-to-duct anastomotic stricture after liver transplantation: Outcomes of a nationwide survey. <i>Liver International</i> , 2019, 39, 1355-1362.	1.9	18
79	Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. <i>Gut</i> , 2019, 68, 130-139.	6.1	150
80	Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2019, 69, 107-120.	3.6	433
81	pH regulators to target the tumor immune microenvironment in human hepatocellular carcinoma. <i>Oncimmunology</i> , 2018, 7, e1445452.	2.1	54
82	Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. <i>Lancet Oncology</i> , The, 2018, 19, 682-693.	5.1	285
83	EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2018, 69, 182-236.	1.8	6,153
84	Vascular invasion and survival after liver transplantation for hepatocellular carcinoma: a study from the European Liver Transplant Registry. <i>Hpb</i> , 2018, 20, 768-775.	0.1	44
85	Locoregional treatments before liver transplantation for hepatocellular carcinoma: a study from the European Liver Transplant Registry. <i>Transplant International</i> , 2018, 31, 531-539.	0.8	41
86	Alpha-fetoprotein in liver transplantation for hepatocellular carcinoma: The lower, the better. <i>Hepatology</i> , 2018, 68, 775-777.	3.6	8
87	Relative Survival Instead of Overall Survival Should Be Used as Outcome When Analyzing the Effect of Age After Treatment of Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2018, 268, e76.	2.1	0
88	Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion. <i>Journal of Hepatology</i> , 2018, 68, 724-732.	1.8	100
89	Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. <i>Gastroenterology</i> , 2018, 155, 479-489.e7.	0.6	54
90	Reply to: "Validation of response to yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion". <i>Journal of Hepatology</i> , 2018, 69, 260-261.	1.8	1

#	ARTICLE	IF	CITATIONS
91	Proposal of Prognostic Survival Models before and after Liver Resection for Hepatocellular Carcinoma in Potentially Transplantable Patients. Journal of the American College of Surgeons, 2018, 226, 1147-1159.	0.2	13
92	Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials. British Journal of Cancer, 2018, 118, 955-965.	2.9	17
93	Pro (With Caution): Extended oncologic indications in liver transplantation. Liver Transplantation, 2018, 24, 98-103.	1.3	24
94	Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma. Gastroenterology, 2018, 154, 128-139.	0.6	417
95	85. Treatment of hepatocarcinoma with 90Y glass microspheres: Safety and indication of prolonged overall survival thanks to two compartment dosimetric treatment planning. Physica Medica, 2018, 56, 114-115.	0.4	0
96	The SIRveNIB and SARAH trials, radioembolization vs. sorafenib in advanced HCC patients: reasons for a failure, and perspectives for the future. Hepatobiliary Surgery and Nutrition, 2018, 7, 487-489.	0.7	39
97	Hepatocellular Carcinoma in Abernethy Malformation: A Rare Occurrence of Congenital Complete Portosystemic Shunt. Journal of Vascular and Interventional Radiology, 2018, 29, 1775-1778.	0.2	3
98	Systemic Administration and Targeted Delivery of Immunogenic Oncolytic Adenovirus Encapsulated in Extracellular Vesicles for Cancer Therapies. Viruses, 2018, 10, 558.	1.5	73
99	Liver Transplantation and Hepatic Resection can Achieve Cure for Hepatocellular Carcinoma. Annals of Surgery, 2018, 268, 868-875.	2.1	127
100	Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. Journal of Hepatology, 2018, 69, 1284-1293.	1.8	360
101	Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with <i>RAS</i> -Mutated Hepatocellular Carcinoma. Clinical Cancer Research, 2018, 24, 4650-4661.	3.2	63
102	Clinical Options for Treatment of Hepatocellular Carcinoma. , 2018, , 95-105.		0
103	Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis. BMC Cancer, 2018, 18, 715.	1.1	15
104	A Longitudinal Investigation of Posttraumatic Growth and Quality of Life in Liver Transplant Recipients. Progress in Transplantation, 2018, 28, 236-243.	0.4	12
105	Reply. Gastroenterology, 2018, 154, 2276-2277.	0.6	1
106	Occurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antivirals. Journal of Hepatology, 2017, 67, 415-417.	1.8	7
107	Hepatic Epithelioid Hemangioendothelioma and Adult Liver Transplantation: Proposal for a Prognostic Score Based on the Analysis of the ELTR-ELITA Registry. Transplantation, 2017, 101, 555-564.	0.5	75
108	Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. Gastroenterology, 2017, 153, 812-826.	0.6	650

#	ARTICLE	IF	CITATIONS
109	Management of biliary anastomotic strictures after liver transplantation (BASALT study): A nationwide Italian survey. <i>Liver Transplantation</i> , 2017, 23, 257-261.	1.3	16
110	Loss of succinate dehydrogenase subunit B (SDHB) as a prognostic factor in advanced ileal well-differentiated neuroendocrine tumors. <i>Endocrine</i> , 2017, 57, 512-517.	1.1	8
111	Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation. <i>Gastroenterology</i> , 2017, 152, 880-894.e6.	0.6	290
112	Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver. <i>European Journal of Surgical Oncology</i> , 2017, 43, 380-387.	0.5	51
113	A matched pair analysis of multicenter longterm follow-up after split-liver transplantation with extended right grafts. <i>Liver Transplantation</i> , 2017, 23, 1384-1395.	1.3	21
114	Average treatment effect of hepatic resection versus locoregional therapies for hepatocellular carcinoma. <i>British Journal of Surgery</i> , 2017, 104, 1704-1712.	0.1	21
115	Donor safety in living donor liver donation: An Italian multicenter survey. <i>Liver Transplantation</i> , 2017, 23, 184-193.	1.3	55
116	Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases. <i>Clinical Colorectal Cancer</i> , 2017, 16, e191-e198.	1.0	12
117	Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from pre- to post-liver transplant: a real-life strategy. <i>Liver International</i> , 2017, 37, 678-683.	1.9	10
118	The place of liver transplantation in the treatment of hepatic metastases from neuroendocrine tumors: Pros and cons. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2017, 18, 473-483.	2.6	26
119	Thrombosis after liver transplantation for hepatocellular carcinoma. <i>PLoS ONE</i> , 2017, 12, e0186699.	1.1	8
120	Transarterial chemoembolization using 40 µm drug eluting beads for hepatocellular carcinoma. <i>World Journal of Radiology</i> , 2017, 9, 245.	0.5	25
121	Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis. <i>PLoS ONE</i> , 2016, 11, e0151662.	1.1	56
122	Impact of home enteral nutrition in malnourished patients with upper gastrointestinal cancer: A multicentre randomised clinical trial. <i>European Journal of Cancer</i> , 2016, 64, 107-112.	1.3	60
123	The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors. <i>American Journal of Transplantation</i> , 2016, 16, 2892-2902.	2.6	151
124	Propensity score analysis of outcomes following laparoscopic or open liver resection for hepatocellular carcinoma. <i>British Journal of Surgery</i> , 2016, 103, 871-880.	0.1	130
125	Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma. <i>Liver International</i> , 2016, 36, 1033-1042.	1.9	28
126	Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 645-653.	1.4	71

#	ARTICLE	IF	CITATIONS
127	External validation of an individual prognostic calculator after transarterial chemoembolization for hepatocellular carcinoma. Liver International, 2016, 36, 1231-1231.	1.9	4
128	Squaring the circle of selection and allocation in liver transplantation for HCC: An adaptive approach. Hepatology, 2016, 63, 1707-1717.	3.6	110
129	Importance of primary indication and liver function between stages: results of a multicenter Italian audit of ALPPS 2012-2014. Hpb, 2016, 18, 419-427.	0.1	56
130	Endoscopic ultrasound-guided esophagoenterostomy for a completely obstructed surgical anastomosis. Endoscopy, 2016, 48, E1-E2.	1.0	24
131	Endoscopic ultrasound-guided fine needle aspiration of splenic vein thrombosis: a novel approach to the portal venous system. Endoscopy, 2016, 48, E40-E41.	1.0	4
132	Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes. Future Oncology, 2016, 12, 1251-1260.	1.1	29
133	Liver transplantation for "very early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment. Hepatology, 2016, 64, 1178-1188.	3.6	262
134	Effect of age on survival in patients undergoing resection of hepatocellular carcinoma. British Journal of Surgery, 2016, 103, e93-e99.	0.1	53
135	Liver transplantation for adenomatosis: European experience. Liver Transplantation, 2016, 22, 516-526.	1.3	41
136	Hierarchic Interaction of Factors Associated With Liver Decompensation After Resection for Hepatocellular Carcinoma. JAMA Surgery, 2016, 151, 846.	2.2	106
137	Expert opinion on advanced techniques for hemostasis in liver surgery. European Journal of Surgical Oncology, 2016, 42, 1597-1607.	0.5	8
138	Reply. Hepatology, 2016, 63, 1054-1055.	3.6	2
139	Surgical management of duodenal stump fistula after elective gastrectomy for malignancy: an Italian retrospective multicenter study. Gastric Cancer, 2016, 19, 273-279.	2.7	24
140	Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma. Transplantation, 2016, 100, 116-125.	0.5	339
141	Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma. Clinical Cancer Research, 2016, 22, 291-300.	3.2	185
142	Strict Selection Alone of Patients Undergoing Liver Transplantation for Hilar Cholangiocarcinoma Is Associated with Improved Survival. PLoS ONE, 2016, 11, e0156127.	1.1	70
143	Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses. Oncotarget, 2016, 7, 72343-72355.	0.8	57
144	Development of a prognostic scoring system for resectable hepatocellular carcinoma. World Journal of Gastroenterology, 2016, 22, 8194.	1.4	7

#	ARTICLE	IF	CITATIONS
145	Extended survival of patients with persistently suppressed hepatitis B transplanted for hepatocellular carcinoma. <i>Liver International</i> , 2015, 35, 2187-2193.	1.9	2
146	Dissecting EASL/AASLD Recommendations With a More Careful Knife. <i>Annals of Surgery</i> , 2015, 262, e17-e18.	2.1	16
147	Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases. <i>Medical Oncology</i> , 2015, 32, 182.	1.2	22
148	A Multistep, Consensus-Based Approach to Organ Allocation in Liver Transplantation: Toward a “Blended Principle Model”. <i>American Journal of Transplantation</i> , 2015, 15, 2552-2561.	2.6	164
149	Authors’ response to the letter: Liver resection for patients with hepatocellular carcinoma and macrovascular invasion, multiple tumours or portal hypertension by Zhong<i>et al</i>. <i>Gut</i> , 2015, 64, 522-522.	6.1	5
150	Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. <i>Nature Communications</i> , 2015, 6, 6087.	5.8	240
151	DNA methylation-based prognosis and predictors in hepatocellular carcinoma. <i>Hepatology</i> , 2015, 61, 1945-1956.	3.6	367
152	Unique Genomic Profile of Fibrolamellar Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2015, 148, 806-818.e10.	0.6	109
153	Repeated transarterial chemoembolization: An overfitting effort?. <i>Journal of Hepatology</i> , 2015, 62, 1440-1442.	1.8	18
154	Progenitor cell markers predict outcome of patients with hepatocellular carcinoma beyond Milan criteria undergoing liver transplantation. <i>Journal of Hepatology</i> , 2015, 63, 1368-1377.	1.8	64
155	Radioembolization of hepatocarcinoma with 90Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1718-1738.	3.3	128
156	Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review. <i>Future Oncology</i> , 2015, 11, 1947-1959.	1.1	9
157	Liver cancer: Approaching a personalized care. <i>Journal of Hepatology</i> , 2015, 62, S144-S156.	1.8	239
158	Surgical resection for hepatocellular carcinoma: Moving from what can be done to what is worth doing. <i>Hepatology</i> , 2015, 62, 340-342.	3.6	22
159	Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. <i>Nature Genetics</i> , 2015, 47, 505-511.	9.4	1,372
160	Liver transplantation for neuroendocrine tumour liver metastases. <i>Hpb</i> , 2015, 17, 23-28.	0.1	78
161	Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet Oncology</i> , The, 2015, 16, 1344-1354.	5.1	809
162	When should a liver resection be performed in patients with liver metastases from neuroendocrine tumours? A systematic review with practice recommendations. <i>Hpb</i> , 2015, 17, 17-22.	0.1	59

#	ARTICLE	IF	CITATIONS
163	Transarterial Chemoembolization for Hepatocellular Carcinoma with a New Generation of Beads: Clinicalâ€“Radiological Outcomes and Safety Profile. CardioVascular and Interventional Radiology, 2015, 38, 129-134.	0.9	59
164	Intrahepatic Flow Redistribution in Patients Treated with Radioembolization. CardioVascular and Interventional Radiology, 2015, 38, 322-328.	0.9	21
165	Early Hepatocellular Carcinoma on the Procrustean Bed of Ablation, Resection, and Transplantation. Seminars in Liver Disease, 2014, 34, 415-426.	1.8	60
166	Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study. Annals of Oncology, 2014, 25, 1597-1603.	0.6	59
167	Toward a Better Liver Graft Allocation That Accounts for Candidates With and Without Hepatocellular Carcinoma. American Journal of Transplantation, 2014, 14, 2221-2227.	2.6	54
168	Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 223-230.	3.3	88
169	Hepatocellular carcinoma: clinical frontiers and perspectives. Gut, 2014, 63, 844-855.	6.1	1,180
170	The dosimetric importance of the number of 90Y microspheres in liver transarterial radioembolization (TARE). European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 634-638.	3.3	25
171	Ewing sarcoma of the small bowel: a study of seven cases, including one with the uncommonly reported <i>EWSR1-ATM</i> translocation. Histopathology, 2014, 64, 1014-1026.	1.6	19
172	Current challenges in liver transplantation for hepatocellular carcinoma. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 867-879.	1.0	30
173	Reply to: â€œTime is a crucial factor for the use of oncological treatment for post-transplantation recurrence of hepatocellular carcinomaâ€œ. Journal of Hepatology, 2014, 60, 230-231.	1.8	0
174	Reply to: â€œSorafenib efficacy for treatment of HCC recurrence after liver transplantation is an open issueâ€œ. Journal of Hepatology, 2014, 60, 682-683.	1.8	1
175	A Bayesian methodology to improve prediction of early graft loss after liver transplantation derived from the Liver Match study. Digestive and Liver Disease, 2014, 46, 340-347.	0.4	18
176	Thoracic paravertebral anesthesia for percutaneous radiofrequency ablation of hepatic tumors. Journal of Clinical Anesthesia, 2014, 26, 271-275.	0.7	20
177	A Prospective Policy Development to Increase Split-Liver Transplantation for 2 Adult Recipients. Annals of Surgery, 2014, 259, 157-165.	2.1	53
178	Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study. European Journal of Cancer, 2013, 49, 3412-3419.	1.3	218
179	Transhepatic anterior approach to the inferior vena cava in large retroperitoneal tumors resected en bloc with the right liver lobe. Surgery, 2013, 154, 1061-1068.	1.0	10
180	Multiagent imaging of liver tumors with reference to intra-arterial radioembolization. Clinical and Translational Imaging, 2013, 1, 423-432.	1.1	3

#	ARTICLE	IF	CITATIONS
181	Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: A case-control study. <i>Journal of Hepatology</i> , 2013, 59, 59-66.	1.8	128
182	Prognostic Role of Pancreatic Metastases From Renal Cell Carcinoma: Results From an Italian Center. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 484-488.	0.9	41
183	Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different Outcomes. <i>Gastroenterology</i> , 2013, 144, 829-840.	0.6	438
184	Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: Biological lessons, current challenges, and clinical perspectives. <i>Hepatology</i> , 2013, 58, 2188-2197.	3.6	154
185	Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 study. <i>Hepatology</i> , 2013, 57, 1826-1837.	3.6	428
186	Resection of hepatocellular cancer $\leq 2$ cm: Results from two Western centers. <i>Hepatology</i> , 2013, 57, 1426-1435.	3.6	326
187	Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions. <i>Seminars in Liver Disease</i> , 2013, 32, 348-359.	1.8	508
188	Reply:. <i>Hepatology</i> , 2013, 58, 452-453.	3.6	0
189	Well-differentiated neuroendocrine tumor of tailgut cyst. A rare entity with controversial medical opportunities. <i>Tumori</i> , 2013, 99, e148-51.	0.6	4
190	Succinate Dehydrogenase B Subunit Immunohistochemical Expression Predicts Aggressiveness in Well Differentiated Neuroendocrine Tumors of the Ileum. <i>Cancers</i> , 2012, 4, 808-820.	1.7	6
191	Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 173-185.	1.4	57
192	Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib. <i>Clinical Cancer Research</i> , 2012, 18, 4997-5007.	3.2	251
193	EASL/EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2012, 56, 908-943.	1.8	5,214
194	Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. <i>Journal of Hepatology</i> , 2012, 56, 1080-1088.	1.8	109
195	Liver transplantation for unresectable hepatocellular carcinoma in normal livers. <i>Journal of Hepatology</i> , 2012, 57, 297-305.	1.8	49
196	Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial. <i>Journal of Hepatology</i> , 2012, 57, 821-829.	1.8	736
197	Liver Retransplantation in Adults: The Largest Multicenter Italian Study. <i>PLoS ONE</i> , 2012, 7, e46643.	1.1	22
198	A dosimetric treatment planning strategy in radioembolization of hepatocarcinoma with $^{90}\text{Y}$ glass microspheres. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 56, 503-8.	0.4	42

#	ARTICLE	IF	CITATIONS
199	Combining Clinical, Pathology, and Gene Expression Data to Predict Recurrence of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2011, 140, 1501-1512.e2.	0.6	389
200	MicroRNA-Based Classification of Hepatocellular Carcinoma and Oncogenic Role of miR-517a. <i>Gastroenterology</i> , 2011, 140, 1618-1628.e16.	0.6	205
201	Liver Match, a prospective observational cohort study on liver transplantation in Italy: Study design and current practice of donorâ€™recipient matching. <i>Digestive and Liver Disease</i> , 2011, 43, 155-164.	0.4	69
202	Importance of early nutritional screening in patients with gastric cancer. <i>British Journal of Nutrition</i> , 2011, 106, 1773-1778.	1.2	59
203	Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization. <i>Cancer Treatment Reviews</i> , 2011, 37, 212-220.	3.4	460
204	Gene-expression signature of vascular invasion in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2011, 55, 1325-1331.	1.8	133
205	Principles for the best multidisciplinary meetings. <i>Lancet Oncology</i> , The, 2011, 12, 323-325.	5.1	24
206	Balancing Donor and Recipient Risk Factors in Liver Transplantation: The Value of D-MELD With Particular Reference to HCV Recipients. <i>American Journal of Transplantation</i> , 2011, 11, 2724-2736.	2.6	86
207	Milan criteria in liver transplantation for hepatocellular carcinoma: An evidence-based analysis of 15 years of experience. <i>Liver Transplantation</i> , 2011, 17, S44-S57.	1.3	471
208	Summary of candidate selection and expanded criteria for liver transplantation for hepatocellular carcinoma: A review and consensus statement. <i>Liver Transplantation</i> , 2011, 17, S81-S89.	1.3	51
209	Evidence of Distinct Tumour-Propagating Cell Populations with Different Properties in Primary Human Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2011, 6, e21369.	1.1	56
210	Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of Milan. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 55, 168-97.	0.4	101
211	Simultaneous characterization of progenitor cell compartments in adult human liver. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2010, 77A, 31-40.	1.1	8
212	Duodenal Fistula after Elective Gastrectomy for Malignant Disease. <i>Journal of Gastrointestinal Surgery</i> , 2010, 14, 805-811.	0.9	53
213	A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. <i>BMC Cancer</i> , 2010, 10, 190.	1.1	146
214	Partial hepatectomy versus radiofrequency ablation for hepatocellular carcinoma: Confirming the trial that will never be, and some comments on the indications for liver resection. <i>Hepatology</i> , 2010, 51, 1116-1118.	3.6	36
215	The challenges of liver transplantation for hepatocellular carcinoma on cirrhosis. <i>Transplant International</i> , 2010, 23, 712-722.	0.8	45
216	8. Multidisciplinary Approach for the Treatment of Neuroendocrine Tumors. <i>Tumori</i> , 2010, 96, 833-846.	0.6	24

#	ARTICLE	IF	CITATIONS
217	Massive APOBEC3 Editing of Hepatitis B Viral DNA in Cirrhosis. PLoS Pathogens, 2010, 6, e1000928.	2.1	145
218	IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. Journal of Hepatology, 2010, 52, 550-559.	1.8	211
219	Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: A proof of principle. Journal of Hepatology, 2010, 52, 771-775.	1.8	82
220	Exploiting liver immunity for the prevention of hepatic metastases. Journal of Hepatology, 2010, 53, 596-598.	1.8	2
221	miR-221 overexpression contributes to liver tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 264-269.	3.3	679
222	Multidisciplinary approach for the treatment of neuroendocrine tumors. Tumori, 2010, 96, 833-46.	0.6	12
223	CT cholangiography: Assessment of feasibility and diagnostic reliability. European Journal of Radiology, 2009, 72, 114-117.	1.2	10
224	Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. Journal of Hepatology, 2009, 51, 725-733.	1.8	206
225	Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncology, The, 2009, 10, 35-43.	5.1	1,920
226	Milan criteria, up-to-seven criteria, and the illusion of a rescue package for patients with liver cancer – Authors' reply. Lancet Oncology, The, 2009, 10, 208-209.	5.1	1
227	Liver Transplantation for Hepatocellular Carcinoma. Annals of Surgical Oncology, 2008, 15, 1001-1007.	0.7	249
228	Sorafenib in Advanced Hepatocellular Carcinoma. New England Journal of Medicine, 2008, 359, 378-390.	13.9	12,004
229	Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma. Gastroenterology, 2008, 135, 1972-1983.e11.	0.6	644
230	Focal Gains of <i>VEGFA</i> and Molecular Classification of Hepatocellular Carcinoma. Cancer Research, 2008, 68, 6779-6788.	0.4	589
231	Chromosome instability in human hepatocellular carcinoma depends on p53 status and aflatoxin exposure. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2008, 653, 6-13.	0.9	50
232	Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma. New England Journal of Medicine, 2008, 359, 1995-2004.	13.9	1,148
233	Thyroid as a Target of Metastases. A Case of Foregut Neuroendocrine Carcinoma with Multiple Abdominal Metastases and a Thyroid Localization after 21 Years. Tumori, 2008, 94, 110-113.	0.6	17
234	The Place of Liver Transplantation in the Treatment of Hepatic Epitheloid Hemangioendothelioma. Annals of Surgery, 2007, 246, 949-957.	2.1	165

#	ARTICLE	IF	CITATIONS
235	Phenomenology and Emotional Impact of Neuropsychiatric Symptoms in Orthotopic Liver Transplant for Hepatocellular Carcinoma. Transplantation Proceedings, 2007, 39, 1564-1568.	0.3	3
236	First-Line Treatment for Hepatocellular Carcinoma: Resection or Transplantation?. Transplantation Proceedings, 2007, 39, 2271-2273.	0.3	15
237	Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. Journal of Hepatology, 2007, 46, 645-654.	1.8	75
238	Neuroendocrine tumors metastatic to the liver: How to select patients for liver transplantation?. Journal of Hepatology, 2007, 47, 460-466.	1.8	290
239	Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology, 2007, 45, 938-947.	3.6	632
240	Results of liver transplantation: With or without milan criteria?. Liver Transplantation, 2007, 13, S44-S47.	1.3	66
241	A Molecular Signature to Discriminate Dysplastic Nodules From Early Hepatocellular Carcinoma in HCV Cirrhosis. Gastroenterology, 2006, 131, 1758-1767.	0.6	379
242	A Clinical Outcome-Based Prospective Study on Venous Thromboembolism After Cancer Surgery. Annals of Surgery, 2006, 243, 89-95.	2.1	595
243	Transthyretin RNA profiling in livers from transplanted patients affected by familial amyloidotic polyneuropathy, and identification of a dual transcription start point. Liver International, 2006, 26, 211-220.	1.9	3
244	Percutaneous Transhepatic Biliary Drainage in the Management of Postsurgical Biliary Leaks in Patients with Nondilated Intrahepatic Bile Ducts. CardioVascular and Interventional Radiology, 2006, 29, 380-388.	0.9	66
245	Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology, 2006, 44, 1543-1554.	3.6	347
246	Split and whole liver transplantation outcomes: A comparative cohort study. Liver Transplantation, 2006, 12, 402-410.	1.3	106
247	Living donor liver transplantation for hepatocellular carcinoma exceeding conventional criteria: Questions, answers and demands for a common language. Liver Transplantation, 2006, 12, 896-898.	1.3	36
248	Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. Liver Transplantation, 2005, 11, 532-538.	1.3	78
249	Resection, transplantation, either, or both? Other pieces of the puzzle. Liver Transplantation, 2005, 11, 1177-1180.	1.3	16
250	ETOPOSIDE, CISPLATIN, EPIRUBICIN CHEMOTHERAPY IN THE TREATMENT OF PEDIATRIC LIVER TUMORS. Pediatric Hematology and Oncology, 2005, 22, 189-198.	0.3	6
251	Resection and Liver Transplantation for Hepatocellular Carcinoma. Seminars in Liver Disease, 2005, 25, 181-200.	1.8	1,043
252	Natural Killer and NK-Like T-Cell Activation in Colorectal Carcinoma Patients Treated with Autologous Tumor-Derived Heat Shock Protein 96. Cancer Research, 2005, 65, 3942-3949.	0.4	47

#	ARTICLE	IF	CITATIONS
253	Heat Shock Proteins and Their Use as Anticancer Vaccines. <i>Clinical Cancer Research</i> , 2004, 10, 8142-8146.	3.2	62
254	Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer. <i>Cancer Immunology, Immunotherapy</i> , 2004, 53, 227-233.	2.0	116
255	94 Prospective randomised trial on IFN-therapy for the secondary prevention of HCC recurrence after curative resection in HCV related cirrhosis. Preliminary report. <i>Journal of Hepatology</i> , 2004, 40, 34.	1.8	4
256	Radiofrequency Ablation of Small Hepatocellular Carcinoma in Cirrhotic Patients Awaiting Liver Transplantation. <i>Annals of Surgery</i> , 2004, 240, 900-909.	2.1	452
257	Nonhepatic glucose production in humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2004, 286, E129-E135.	1.8	64
258	<i>Helicobacter</i> species sequences in liver samples from patients with and without hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2004, 10, 598.	1.4	92
259	Solid-pseudopapillary tumor of the pancreas (Frantz tumor) in children. <i>Medical and Pediatric Oncology</i> , 2003, 41, 74-76.	1.0	35
260	Fibroblastic reticular cell tumor of the spleen: report of a case and review of the entity. <i>Human Pathology</i> , 2003, 34, 954-957.	1.1	38
261	Human Tumor-Derived Heat Shock Protein 96 Mediates In Vitro Activation and In Vivo Expansion of Melanoma- and Colon Carcinoma-Specific T Cells. <i>Journal of Immunology</i> , 2003, 171, 3467-3474.	0.4	116
262	Assessment of insulin sensitivity based on a fasting blood sample in men with liver cirrhosis before and after liver transplantation <sup>1</sup> . <i>Transplantation</i> , 2003, 76, 697-702.	0.5	15
263	Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. <i>Clinical Cancer Research</i> , 2003, 9, 3235-45.	3.2	197
264	Amino Acid Kinetics During the Anhepatic Phase of Liver Transplantation. <i>Diabetes</i> , 2002, 51, 1690-1698.	0.3	10
265	Candidates for liver transplantation for cancer: physical, psychological, and social conditions <sup>1</sup> . <i>Transplantation</i> , 2002, 73, 1627-1635.	0.5	9
266	Feasibility of Peritonectomy Associated with Intraperitoneal Hyperthermic Perfusion in Patients with Pseudomyxoma Peritonei. <i>Tumori</i> , 2002, 88, 370-375.	0.6	17
267	Resting energy expenditure in diabetic and nondiabetic patients with liver cirrhosis: relation with insulin sensitivity and effect of liver transplantation and immunosuppressive therapy. <i>American Journal of Clinical Nutrition</i> , 2002, 76, 541-548.	2.2	41
268	Post-absorptive and insulin-mediated muscle protein metabolism in liver-transplanted patients. <i>Acta Diabetologica</i> , 2002, 39, 203-208.	1.2	6
269	Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. <i>Transplantation Proceedings</i> , 2001, 33, 1355-1357.	0.3	127
270	Liver transplantation for small hepatocellular carcinoma in cirrhosis: analysis of our experience. <i>Transplantation Proceedings</i> , 2001, 33, 1442-1444.	0.3	55

#	ARTICLE	IF	CITATIONS
271	Experience with radiofrequency ablation of small hepatocellular carcinomas before liver transplantation. Transplantation Proceedings, 2001, 33, 1516-1517.	0.3	54
272	Resection versus transplantation for liver metastases from neuroendocrine tumors. Transplantation Proceedings, 2001, 33, 1537-1539.	0.3	93
273	Mutation and transcription analysis of transthyretin gene in Italian families with hereditary amyloidosis: a putative novel "hot spot"™ in codon 47. Clinical Genetics, 2001, 57, 284-290.	1.0	11
274	Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: Effect of liver transplantation. Hepatology, 2000, 31, 694-703.	3.6	114
275	Percutaneous Radio-frequency Thermal Ablation of Nonresectable Hepatocellular Carcinoma after Occlusion of Tumor Blood Supply. Radiology, 2000, 217, 119-126.	3.6	490
276	Effect of TT Virus Infection on Hepatocellular Carcinoma Development: Results of a Euro-Asian Survey. Journal of Infectious Diseases, 2000, 181, 1138-1142.	1.9	35
277	Chemoradiotherapy as preoperative treatment in locally advanced unresectable pancreatic cancer patients: results of a feasibility study11Data management by Italian Trials in Medical Oncology (I.T.M.O.) Scientific Service.. International Journal of Radiation Oncology Biology Physics, 1999, 45, 285-289.	0.4	56
278	RECURRENCE OF DESMOID TUMOR IN A MULTIVISCERAL TRANSPLANT PATIENT WITH GARDNER'S SYNDROME. Transplantation, 1999, 67, 1197-1199.	0.5	15
279	Increased Retinol Binding Protein in the Sera of Patients with Severe Ischemic Damage of the Liver after Transplantation. Clinical Biochemistry, 1998, 31, 113-116.	0.8	3
280	Pattern and management of recurrent hepatocellular carcinoma after liver transplantation. Journal of Hepato-Biliary-Pancreatic Surgery, 1998, 5, 29-34.	2.0	137
281	Effect of liver transplantation in cirrhotic diabetic patients. Transplantation Proceedings, 1998, 30, 1868.	0.3	2
282	Bone Lesion in a Patient with Transplanted Liver for a Metastatic Carcinoid. The Role of Somatostatin Receptor Scintigraphy. Tumori, 1998, 84, 82-84.	0.6	5
283	Spontaneous hypoglycaemia after pancreas transplantation in Type 1 diabetes mellitus. Diabetic Medicine, 1998, 15, 991-996.	1.2	1
284	Hepatocellular carcinoma in patients who undergo liver transplantation: sensitivity of CT with iodized oil.. Radiology, 1997, 203, 457-460.	3.6	55
285	Renal-splenic shunt for infrahepatic caval occlusion after piggy-back liver transplantation. Transplant International, 1997, 10, 392-394.	0.8	3
286	Prophylaxis against HCV recurrence after liver transplantation: Effect of interferon and ribavirin combination. Transplantation Proceedings, 1997, 29, 519-521.	0.3	92
287	Renal-splenic shunt for intrahepatic caval occlusion after piggy-back liver transplantation. Transplant International, 1997, 10, 392-394.	0.8	3
288	Preoperative serum levels of wild-type and hepatitis B e antigen-negative hepatitis B virus (HBV) and graft infection after liver transplantation for HBV-related hepatocellular carcinoma. Journal of Viral Hepatitis, 1997, 4, 235-242.	1.0	6

#	ARTICLE	IF	CITATIONS
289	Metabolic effects of liver transplantation in cirrhotic patients.. Journal of Clinical Investigation, 1997, 99, 692-700.	3.9	45
290	Regulation of glucose homeostasis in humans with denervated livers.. Journal of Clinical Investigation, 1997, 100, 931-941.	3.9	95
291	Psychosocial adaptation after liver transplantation with particularreference to recipients aware of their cancer. European Journal of Surgical Oncology, 1996, 22, 240-244.	0.5	4
292	Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis. New England Journal of Medicine, 1996, 334, 693-700.	13.9	6,573
293	The Role of Somatostatin Analogues in the Treatment of Gastro-Enteropancreatic Endocrine Tumours. Digestion, 1996, 57, 72-76.	1.2	14
294	Carcinoid syndrome. Pediatric Surgery International, 1996, 11, 398-399.	0.6	0
295	Risk of HBV reinfection after liver transplantation in HBsAg positive cirrhosis: Primary hepatocellular carcinoma is not a predictor for HBV recurrence. Liver, 1996, 16, 117-122.	0.1	22
296	Metabolic effects of successful intraportal islet transplantation in insulin-dependent diabetes mellitus.. Journal of Clinical Investigation, 1996, 97, 2611-2618.	3.9	63
297	A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) Group. Annals of Oncology, 1995, 6, 77-79.	0.6	82
298	Combined liver and pancreatic islets transplantation in man using cyclosporin immunosuppression. Transplant International, 1994, 7, 409-411.	0.8	4
299	Chemoembolization of hepatocellular carcinoma in patients who undergo liver transplantation.. Radiology, 1994, 192, 687-690.	3.6	92
300	Immunocytochemical Detection and Characterization of Intrahepatic Human Pancreatic Islets after Combined Liver-Islet Allotransplantation. Cell Transplantation, 1994, 3, 499-508.	1.2	12
301	Milan multicenter experience in liver transplantation for hepatitis C-related cirrhosis: report of 105 cases. Transplantation Proceedings, 1994, 26, 3582-4.	0.3	4
302	Hepatic resection for hepatocellular carcinoma. Journal of Surgical Oncology, 1993, 53, 62-66.	0.8	6
303	Reappraisal of the role of liver transplantation in the treatment of hepatocellular carcinoma arising in cirrhosis. Journal of Surgical Oncology, 1993, 53, 83-86.	0.8	3
304	Prognostic factors in patients affected by hepatocellular carcinoma treated with systemic chemotherapy: The experience of the National Cancer Institute of Milan. Annals of Oncology, 1993, 4, 489-493.	0.6	15
305	Confirmation of graft-versus-host disease after liver transplantation by PCR HLA-typing. Transplantation, 1993, 55, 423-5.	0.5	8
306	HEPATOTROPHIC EFFECTS OF FK506 IN DOGS. Transplantation, 1991, 51, 67-69.	0.5	82

#	ARTICLE	IF	CITATIONS
307	Quantitation of estrogen and androgen receptors in hepatocellular carcinoma and adjacent normal human liver. Digestive Diseases and Sciences, 1991, 36, 1303-1308.	1.1	49
308	Further steps of hepatic stimulatory substance purification. Digestive Diseases and Sciences, 1991, 36, 674-680.	1.1	28
309	Cyclosporine and liver regeneration studied by in vivo <sup>31</sup> P nuclear magnetic resonance spectroscopy. Digestive Diseases and Sciences, 1991, 36, 687-692.	1.1	3
310	Role of estrogens and epidermal growth factor in hepatocellular carcinoma (HCC). Digestive Diseases and Sciences, 1991, 36, 1299-1302.	1.1	6
311	Effect of cyclosporine on hepatic energy status and on fructose metabolism after portacaval shunt in dog as monitored by phosphorus-31 nuclear magnetic resonance spectroscopy in vivo. Hepatology, 1991, 13, 780-785.	3.6	7
312	CHILDBEARING AFTER LIVER TRANSPLANTATION. Transplantation, 1990, 49, 317-320.	0.5	112
313	Hormonal and enzymatic parameters of hepatic regeneration in patients undergoing major liver resections. Hepatology, 1990, 12, 1134-1138.	3.6	58
314	A clinicopathologic study of primary hepatic carcinoid tumors. Cancer, 1990, 65, 1211-1218.	2.0	88
315	hepatic arterial embolization with microencapsulated mitomycin C for unresectable hepatocellular carcinoma in cirrhosis. Cancer, 1990, 66, 228-236.	2.0	26
316	Liver transplantation in patients with previous portasystemic shunt. American Journal of Surgery, 1990, 160, 111-116.	0.9	100
317	FK 506 as a growth control factor. Transplantation Proceedings, 1990, 22, 90-2.	0.3	26
318	Studies of the hepatotrophic qualities of FK 506 and CyA. Transplantation Proceedings, 1990, 22, 93-5.	0.3	17
319	Reappraisal of surgical treatment of small hepatocellular carcinomas in cirrhosis: Clinicopathological study of resection or transplantation. Digestive Diseases and Sciences, 1989, 34, 1571-1575.	1.1	31
320	Estradiol and testosterone levels in patients undergoing partial hepatectomy. Digestive Diseases and Sciences, 1989, 34, 818-822.	1.1	45
321	The effect of estrogen and tamoxifen on hepatocyte proliferation in Vivo and in Vitro. Hepatology, 1989, 9, 614-620.	3.6	136
322	A Modified Technique of Orthotopic Transplant of the Kidney in Rabbits. Journal of Investigative Surgery, 1989, 2, 293-303.	0.6	2
323	Efficacy of Liver Transplantation in Patients with Primary Biliary Cirrhosis. New England Journal of Medicine, 1989, 320, 1709-1713.	13.9	235
324	Pharmacologic Modulation of Experimental Postischemic Hepatic Function. Annals of Surgery, 1989, 209, 200-210.	2.1	34

#	ARTICLE	IF	CITATIONS
325	Transplantation of the liver for metastatic endocrine tumors of the intestine and pancreas. Surgery, Gynecology & Obstetrics, 1989, 168, 107-11.	0.6	68
326	Factors responsible for hepatic artery thrombosis after pediatric liver transplantation. Transplantation Proceedings, 1989, 21, 2466-7.	0.3	38
327	Renal artery reconstruction for harvesting injuries in kidney transplantation with particular reference to the use of vascular allografts. Transplant International, 1988, 1, 80-85.	0.8	14
328	Occurrence of cytomegalovirus hepatitis in liver transplant patients. Journal of Medical Virology, 1988, 24, 423-434.	2.5	59
329	Chordoma: Natural history and treatment results in 33 cases. Journal of Surgical Oncology, 1988, 37, 185-191.	0.8	143
330	Renal artery reconstruction for harvesting injuries in kidney transplantation with particular reference to the use of vascular allografts. Transplant International, 1988, 1, 80-85.	0.8	18
331	Primary lymphoma of the liver showing immunohistochemical evidence of T-cell origin. Digestive Diseases and Sciences, 1988, 33, 1632-1636.	1.1	30
332	Kaposi's sarcoma: Malignant tumor or proliferative disorder?. European Journal of Cancer & Clinical Oncology, 1988, 24, 973-978.	0.9	12
333	Approach to Hepatic Metastases from Colorectal Adenocarcinoma. Seminars in Liver Disease, 1988, 8, 247-253.	1.8	2
334	Prolongation of Pig-to-Dog Renal Xenograft Survival by Modification of the Inflammatory Mediator Response. Annals of Surgery, 1987, 206, 482-495.	2.1	41